Table of Contents Author Guidelines Submit a Manuscript
Pathology Research International
Volume 2014 (2014), Article ID 372653, 8 pages
http://dx.doi.org/10.1155/2014/372653
Research Article

Study Assessing the Quality of Quantification of Estrogen Receptor Protein Expression by Immunohistochemistry and Gene Expression in Breast Cancer

1Translational Cancer Research Unit, GZA Hospitals Sint-Augustinus, Oosterveldlaan 24, 2610 Antwerp, Belgium
2Department of Medical Oncology, University of Antwerp, Universiteitsplein 1, 2610 Antwerp, Belgium
3Department of Oncology, KU Leuven, Herestraat 49, 3000 Leuven, Belgium
4Department of Pathology, AZ Klina Hospital, Augustijnslei 100, 2930 Brasschaat, Belgium
5Department of Pathology, AZ Nikolaas Hospital, Moerlandstraat 1, 9100 Sint-Niklaas, Belgium

Received 22 November 2013; Accepted 30 January 2014; Published 6 March 2014

Academic Editor: Paul J. Van Diest

Copyright © 2014 Sas Leen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. E. V. Jensen, V. C. Jordan, S. E. Hankinson, G. A. Colditz, and W. C. Willett, “The estrogen receptor: a model for molecular medicine,” Cancer Research, vol. 9, pp. 1980–1989, 2003. View at Google Scholar
  2. A. Goldhirsch, M. Colleoni, and R. D. Gelber, “Endocrine therapy of breast cancer,” Annals of Oncology, vol. 13, no. 4, pp. 61–68, 2002. View at Publisher · View at Google Scholar · View at Scopus
  3. A. Goldhirsch, J. H. Glick, R. D. Gelber, A. S. Coates, B. Thürlimann, and H. J. Senn, “Meeting highlights: international expert consensus in the primary therapy of early breast cancer,” Annals of Oncology, vol. 16, pp. 1569–1583, 2005. View at Publisher · View at Google Scholar
  4. V.-J. Bardou, G. Arpino, and R. M. Elledge, “Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases,” Journal of Clinical Oncology, vol. 21, no. 10, pp. 1973–1979, 2003. View at Publisher · View at Google Scholar · View at Scopus
  5. A. Rhodes, B. Jasani, D. M. Barnes, L. G. Bobrow, and K. D. Miller, “Reliability of immunohistochemical demonstration of oestrogen receptors in routine practice: interlaboratory variance in the sensitivity of detection and evaluation of scoring systems,” Journal of Clinical Pathology, vol. 53, no. 2, pp. 125–130, 2000. View at Publisher · View at Google Scholar · View at Scopus
  6. D. C. Allred, J. M. Harvey, M. Berardo, and G. M. Clark, “Prognostic and predictive factors in breast cancer by immunohistochemical analysis,” Modern Pathology, vol. 11, no. 2, pp. 155–168, 1998. View at Google Scholar · View at Scopus
  7. J. M. Harvey, G. M. Clark, C. K. Osborne, and D. C. Allred, “Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer,” Journal of Clinical Oncology, vol. 17, no. 5, pp. 1474–1481, 1999. View at Google Scholar · View at Scopus
  8. O. Brouckaert, R. Paridaens, G. Floris, E. Rakha, K. Osborne, and P. A. Neven, “critical review why assessment of steroid hormone receptors in breast cancer should be quantitative,” Annals of Oncology, vol. 24, pp. 47–53, 2013. View at Google Scholar
  9. C. A. Wells, J. P. Sloane, D. Coleman et al., “Consistency of staining and reporting of oestrogen receptor immunocytochemistry within the European Union—an inter-laboratory study,” Virchows Archiv, vol. 445, no. 2, pp. 119–128, 2004. View at Publisher · View at Google Scholar · View at Scopus
  10. R. von Wasielewski, M. Mengel, M. Nolte, and M. Werner, “Influence of fixation, antibody clones, and signal amplification on steroid receptor analysis,” The Breast Journal, vol. 4, no. 1, pp. 33–40, 1998. View at Google Scholar · View at Scopus
  11. J. H. Williams, B. L. Mepham, and D. H. Wright, “Tissue preparation for immunocytochemistry,” Journal of Clinical Pathology, vol. 50, no. 5, pp. 422–428, 1997. View at Google Scholar · View at Scopus
  12. N. S. Goldstein, M. Ferkowicz, E. Odish, A. Mani, and F. Hastah, “Minimum formalin fixation time for consistent estrogen receptor immunohistochemical staining of invasive breast carcinoma,” American Journal of Clinical Pathology, vol. 120, no. 1, pp. 86–92, 2003. View at Publisher · View at Google Scholar · View at Scopus
  13. T. Oyama, Y. Ishikawa, M. Hayashi, K. Arihiro, and J. Horiguchi, “The effects of fixation, processing and evaluation criteria on immunohistochemical detection of hormone receptors in breast cancer,” Breast Cancer, vol. 14, no. 2, pp. 182–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. D. A. Arber, “Effect of prolonged formalin fixation on the immunohistochemical reactivity of breast markers,” Applied Immunohistochemistry and Molecular Morphology, vol. 10, no. 2, pp. 183–186, 2002. View at Publisher · View at Google Scholar · View at Scopus
  15. L. C. Tong, N. Nelson, J. Tsourigiannis, and A. M. Mulligan, “The effect of prolonged fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and her2 expression in invasive breast cancer: a prospective study,” American Journal of Surgical Pathology, vol. 35, no. 4, pp. 545–552, 2011. View at Publisher · View at Google Scholar · View at Scopus
  16. I. Z. Yldriz-Aktas, D. J. Dabbs, K. L. Cooper, M. Chivukula, K. McManus, and R. Bhargava, “The effect of 96-hour formalin fixation on the immunohistochemical evaluation of estrogen receptor, progesterone receptor, and HER2 expression in invasive breast carcinoma,” American Journal of Clinical Pathology, vol. 137, pp. 691–698, 2012. View at Publisher · View at Google Scholar
  17. F. T. Bosman, A. F. P. M. de Goeij, and M. Rousch, “Quality control in immunocytochemistry: experiences with the oestrogen receptor assay,” Journal of Clinical Pathology, vol. 45, no. 2, pp. 120–124, 1992. View at Google Scholar · View at Scopus
  18. M. C. U. Cheang, D. O. Treaba, C. H. Speers et al., “Immunohistochemical detection using the new rabbit monoclonal antibody SP1 of estrogen receptor in breast cancer is superior to mouse monoclonal antibody 1D5 in predicting survival,” Journal of Clinical Oncology, vol. 24, no. 36, pp. 5637–5644, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Rossi, L. Laurino, A. Furlanetto et al., “A comparative study between a novel category of immunoreagents and the corresponding mouse monoclonal antibodies,” American Journal of Clinical Pathology, vol. 124, no. 2, pp. 295–302, 2005. View at Publisher · View at Google Scholar · View at Scopus
  20. Z. Huang, W. Zhu, G. Szekeres, and H. Xia, “Development of new rabbit monoclonal antibody to estrogen receptor: Immunohistochemical assessment on formalin-fixed, paraffin-embedded tissue sections,” Applied Immunohistochemistry and Molecular Morphology, vol. 13, no. 1, pp. 91–95, 2005. View at Publisher · View at Google Scholar · View at Scopus
  21. G. Santeusanio, A. Mauriello, L. Ventura et al., “Immunohistochemical analysis of estrogen receptors in breast carcinomas using monoclonal antibodies that recognize different domains of the receptor molecule,” Applied Immunohistochemistry and Molecular Morphology, vol. 8, no. 4, pp. 275–284, 2000. View at Publisher · View at Google Scholar · View at Scopus
  22. A. M. Gown, “Current issues in ER and HER2 testing by IHC in breast cancer,” Modern Pathology, vol. 21, no. 2, pp. S8–S15, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Arihiro, S. Umemura, M. Kurosumi et al., “Comparison of evaluations for hormone receptors in breast carcinoma using two manual and three automated immunohistochemical assays,” American Journal of Clinical Pathology, vol. 127, no. 3, pp. 356–365, 2007. View at Publisher · View at Google Scholar · View at Scopus
  24. E. S. Reisenbichler, S. C. Lester, A. Richardson, D. A. Dillon, A. Ly, and J. E. Brock, “Interobserver concordance in implementing the 2010 ASCO/CAP recommendations for reporting ER in breast carcinoma,” American Journal of Clinical Pathology, vol. 140, pp. 487–494, 2013. View at Publisher · View at Google Scholar
  25. P. Roepman, H. M. Horlings, O. Krijgsman et al., “Microarray-based determination of estrogen receptor, progesterone receptor, and HER2 receptor status in breast cancer,” Clinical Cancer Research, vol. 15, no. 22, pp. 7003–7011, 2009. View at Publisher · View at Google Scholar · View at Scopus
  26. S. S. Badve, F. L. Baehner, R. P. Gray et al., “Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory,” Journal of Clinical Oncology, vol. 26, no. 15, pp. 2473–2481, 2008. View at Publisher · View at Google Scholar · View at Scopus
  27. P. B. Vermeulen, S. L. van Laere, and L. Y. Dirix, “How to measure and report the estrogen (and progesterone) receptor in breast cancer,” International Journal of Gynecological Cancer, vol. 16, no. 2, pp. 529–532, 2006. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Cronin, M. Pho, D. Dutta et al., “Measurement of gene expression in archival paraffin-embedded tissues: development and performance of a 92-gene reverse transcriptase-polymerase chain reaction assay,” American Journal of Pathology, vol. 164, no. 1, pp. 35–42, 2004. View at Google Scholar · View at Scopus
  29. S. M. O'Connor, S. Beriwal, D. J. Dabbs, and R. Bhargava, “Concordance between semiquantitative immunohistochemical assay and oncotype DX RT-PCR assay for estrogen and progesterone receptors,” Applied Immunohistochemistry and Molecular Morphology, vol. 18, no. 3, pp. 268–272, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. J. A. Kraus, D. J. Dabbs, S. Beriwal, and R. Bhargava, “Semi-quantitative immunohistochemical assay versus oncotype DX qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study,” Modern Pathology, vol. 25, pp. 869–876, 2012. View at Publisher · View at Google Scholar · View at Scopus
  31. F. J. Esteva, A. A. Sahin, M. Cristofanilli et al., “Prognostic role of a multigene reverse transcriptase-PCR assay in patients with node-negative breast cancer not receiving adjuvant systemic therapy,” Clinical Cancer Research, vol. 11, no. 9, pp. 3315–3319, 2005. View at Publisher · View at Google Scholar · View at Scopus